## 2 Materials and Methods
### Methods  
Blood samples were added to standard sterile polystyrene tubes containing ethylenediaminetetraacetic acid (EDTA) and centrifuged at 4000 rpm for 5 min. Plasma was stored at a temperature of \(-20\)\({}^{\circ}\)C until AOPP was measured. All samples were assayed on the same day. A spectrophotometer UV-Vis JASCO V-550 was used to measure absorbance. The concentration of AOPP was determined by measuring absorbance at 340 nm according to the modified method described for the first time by [PERSON] [3]. This method has been described previously [27]. Figure 1 shows the method of determining the AOPP concentration. Briefly, the reactant mixture for the AOPP assay contains 1.875 mL of 0.2 M citric acid and 0.025 mL of 1.16 M potassium iodide. Then, 1.9 mL of this mixture was added to 100 \(\mu\)L of the test sample, and after 30 min, the absorbance was recorded. The results were expressed as chloramine T equivalents and divided by the level of proteins. Compared to the original method, citric acid was used instead of acetic acid. This modified method is characterized by excellent stability over time.  
\begin{table}
\begin{tabular}{c c} \hline \hline
**Inclusion Criteria** & **Exclusion Criteria** \\ \hline Men or women & Diabetes mellitus \\ Age 18–80 years & Obesity (BMI \textgreater{} 30) \\ Provision of informed consent before any & \\ study-specific procedures & Pregnancy \\ Diagnosis of Myocardial Infarction & Active bleeding \\ History of moderate or severe hepatic & impairment \\ History of major surgery or severe trauma & \\ (within three months) & Kidney disease requiring dialysis \\ Respiratory failure & \\ History of severe chronic heart failure & (NYHA \\ class III or IV) & \\ Taking drugs increasing uric acid production: & diuretes, antitubercular drugs, \\ immunosuppressive agent agents, testosterone, & \\ xylitol, nicotinic acid, and lactate infusion. \\ \hline \hline \end{tabular} BMI: body mass index; NYHA: New York Heart Association Classification.  
\end{table}
Table 1: A list of inclusion and exclusion criteria for participation in the study.  
The Benecheck PLUS Multi Monitoring Device measured serum uric acid (SUA) for both the healthy group and post-myocardial infarction patients. Our study aimed to investigate the potential relationship between uric acid and AOPP among patients experiencing MI. Grounded in the hypothesis that varying serum uric acid levels could differentially correlate with oxidative stress, we strategically categorized MI patients based on their serum uric acid concentrations. To conduct a nuanced analysis, patients were divided into two groups: those with serum uric acid levels greater than 8 mg/dL and those with levels less than 8 mg/dL. This categorization criterion was determined by reviewing the existing literature and our preliminary observations, which suggested a significant shift in the relationship between uric acid levels and AOPP beyond the 8 mg/dL threshold. The threshold of 8 mg/dL was specifically chosen as it is generally recognized as the upper limit of normal, with values exceeding this point considered indicative of hyperuricemia, a condition associated with increased risk for various pathological states, including cardiovascular diseases.